Run a competitive landscape around a decision, not a company list

A competitive landscape fails when it answers “who is active?” but the business needs to know “does this change our program?” The first question produces a database. The second produces a decision.

Define competition before searching

Mechanism alone is rarely enough. Two programs may share a target and compete for neither patients nor capital. Two different mechanisms may compete directly because they pursue the same treatment line, biomarker population and product claim.

The landscape should therefore begin with a comparator rule. State the indication, patient segment, line of therapy, modality boundaries, geography and time horizon. Define the target product profile that competitors could threaten. FDA’s TPP guidance is useful here because it connects proposed claims with the evidence needed to support them (FDA).

ARiDA’s competitive work resolves entities before comparison and combines trial, regulatory, patent, company and scientific evidence in one case. The output is not a flat company list. It separates direct clinical comparators, mechanism precedents, enabling technologies and potential substitutes.

Preserve what was observed

Trial registries are living records. ClinicalTrials.gov provides structured public study data through its API (ClinicalTrials.gov), but a current record is not a historical event log by itself. A defensible monitor stores the retrieval time, relevant fields and prior baseline, then computes field-level changes.

Materiality must be explicit. A contact update is not a development event. A primary completion date moving by nine months may be. A newly disclosed endpoint can change the interpretation of differentiation. A status change may require confirmation from another authoritative source.

Translate signals into model consequences

Every material competitor event should map to a business lever. Those levers include launch timing, eligible population, market share, price, trial feasibility, regulatory precedent and probability of success. The analyst should state the proposed consequence before changing the model.

ARiDA can run the affected scenario and preserve both values: the observed competitor fact and the accepted commercial interpretation. A Phase II initiation may increase crowding while leaving asset value almost unchanged. A superior biomarker strategy may reduce addressable population but increase trial success. A safety failure in the class could weaken the entire target case.

Release a watchlist with reopening rules

The final landscape should tell management which competitors matter, why they matter now and what would change the decision. Each watch item needs an owner, a source, a materiality rule and a destination in the model.

That turns monitoring from a news service into an operating process.